Sandoz, a division of the Swiss pharmaceutical giant Novartis, has finalized a deal to acquire the cephalosporin antibiotics business from GSK (GlaxoSmithKline) for up to $500 million. This acquisition grants Sandoz global rights to three major antibiotic brands: Zinnat, Zinacef, and Fortum in over 100 markets, significantly enhancing its position in the antibiotics market. Exclusions […]
Pharma majors Sanofi and GlaxoSmithKline (GSK) have reached an agreement with the UK government for supplying up to 60 million doses of their jointly developed COVID-19 vaccine candidate. The agreement will be subject to a final contract issued by the British government. The COVID-19 vaccine candidate has been developed by Sanofi in partnership with British […]
French pharma company Sanofi has announced a COVID-19 vaccine partnership with GlaxoSmithKline (GSK) to develop an adjuvanted vaccine for the novel coranavirus, by combining their drug discovery technologies. Sanofi will provide its S-protein Covid-19 antigen based on recombinant DNA technology to the partnership. The technology is said to be used for generating an exact genetic […]
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This strategic acquisition, which was first announced in December 2018, is expected to significantly bolster GSK’s presence in the oncology sector, reinforcing its pharmaceutical business and enhancing its pipeline and commercial […]